RTTNews | Aug 16, 2021 10:00AM EDT

10:00 Monday, August 16, 2021 (RTTNews.com) - Travere Therapeutics, Inc. (TVTX) shares are gaining more than 24 percent after the company reported positive interim results in phase 2 Protect study of Sparsentan in IgA Nephropathy.

The company said the treatment group experienced 49.8 percent mean reduction of proteinuria from baseline and more than threefold reduction of active comparator.

Currently, shares are at $19.24, up 24.53 percent from the previous close of $15.45 on a volume of 11,317,289. The shares have traded in a range of $12.75-$33.09 on average volume of 788,098.

Read the original article on RTTNews ( https://www.rttnews.com/3219087/travere-up-24-on-positive-interim-results-in-sparsentan-in-phase-2-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved